#United States #financial results #BD #Franklin Lakes #Becton Dickinson

BD Reports Strong First Quarter Fiscal 2026 Financial Results

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology firm, announced its financial performance for the first quarter of fiscal 2026, marking an operational success as it concluded on December 31, 2025. The company reported a revenue of $5.3 billion, a 1.6% increase from the previous year’s revenue of $5.2 billion, reflecting a 0.4% growth in constant currency.

Tom Polen, BD's Chairman and CEO, noted that this uptick in performance corresponds to the company's strategic initiatives and enhanced commercial activities across pivotal market sectors. Polen stated, "We achieved stronger-than-expected results in the first quarter, thanks to our disciplined execution and emphasis on broad-based growth."

Key Financial Highlights

• - New BD Revenue: A notable 2.5% growth on a constant currency basis.
• - Earnings per Share: The company reported GAAP diluted earnings per share of $1.34, an impressive increase of 28.8% from $1.04 in Q1 FY2025. Adjusted diluted EPS was at $2.91, down by 15.2% year-over-year.

The positive outlook is bolstered by the anticipated completion of the combination of BD’s Biosciences and Diagnostic Solutions unit with Waters Corporation, an event expected to close today. This merger is seen as a critical milestone in BD's strategic approach to bolstering shareholder value, allowing the company to concentrate on expanding its commercial expertise and launching industry-leading innovations.

Business Highlights and Innovations

Several recent achievements under BD's various operational segments are noteworthy:

• - Medical Essentials: The collaboration between the BD HD Check System and ChemoGLO's LC-MS/MS analysis has pioneered rapid contamination testing for hazardous drugs at healthcare facilities.
• - Connected Care: BD Alaris™ EMR Infusion Interoperability implementation at Duncan Regional Hospital marks a significant advancement in healthcare technology.
• - BioPharma Systems Investment: BD made a decisive investment of $110 million in its Nebraska operations aimed at scaling up production of prefillable syringes, crucial for biologic drugs.
• - Interventional Innovations: The FDA has granted clearance for the EnCor EnCompass™ system for breast biopsies, marking a state-of-the-art addition to BD’s offering.

Fiscal Year 2026 Outlook

Looking forward, BD has reaffirmed its revenue growth projection for fiscal 2026, estimating a moderate growth trajectory within the low single digits, while also providing adjusted diluted EPS guidance aimed at a range of $12.35 to $12.65. Their forecast reflects an analysis of various considerations that could influence their operations, including market dynamics and overarching economic conditions.

Conference Call and Additional Information

BD will host an audio webcast to discuss the complete results in further detail, allowing stakeholders an opportunity to engage directly with the company’s strategic narrative. The session will be accessible live on BD’s investor website at 8 a.m. ET today, February 9, 2026.

BD continues to position itself as a forerunner in medical technology, emphasizing its commitment to innovation that enhances healthcare outcomes while adapting to the evolving needs of the market. With a comprehensive suite of solutions and a robust growth strategy, the company is poised for sustained success into the remainder of fiscal 2026 and beyond.

For more detailed information on BD’s financial statements, please access the official press release and relevant financial tables associated with today’s announcement.